Vandetanib
Small molecule targets EGFR, KDR, PTK6, RET, SRC, TEK via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CAPRELSA | — | 2018-10-12 – 2024-03-07 | fda.gov ↗ |
| Approved | EU (EMA) | Caprelsa | — | 2012-02-16 | europa.eu ↗ |
| Approved | US (FDA) | CAPRELSA | — | 2011-04-06 | fda.gov ↗ |
Trials 102 · started per year
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00681798 Comparator | Jul 2006 → Jun 2009 | pancreatic ductal adenocarcinoma | Sanofi | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00995007 Comparator | Sep 2009 → Jun 2015 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00687297 Comparator | Apr 2008 → Jan 2011 | non-small cell lung carcinoma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT00459043 Comparator | Mar 2007 → Mar 2010 | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04760288 Comparator | Nov 2023 → Oct 2027 | medullary thyroid gland carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT04211337 Comparator | Feb 2020 → May 2023 overdue | medullary thyroid gland carcinoma | Loxo Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01298323 Background | Feb 2011 → Apr 2013 | medullary thyroid gland carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01496313 Comparator | Jun 2012 → Apr 2014 | thyroid cancer | Sanofi | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 114 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vandetanib | “Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.” PMID 22701615 ↗ Jun 201289“BTG-002814 (containing 100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery” PMID 31579027 ↗ Oct 2019 “Tretinoin, Vandetanib, Vemurafenib” NCT02788201 ↗ “ZD6474 (vandetanib) 100mg” NCT00507091 ↗ “ZD6474 (vandetanib) 100mg” NCT00496509 ↗ “ZD6474 (vandetanib) 100mg” NCT00252746 ↗ “Drug: ZD6474 (vandetanib)” NCT00450138 ↗ “ZD6474(Vandetanib) 300 mg” NCT00508001 ↗ “ZD6474 (vandetanib)” NCT00499850 ↗ “ZD6474 (Vandetanib)” NCT00659438 ↗ “ZD6474 (vandetanib)” NCT00358956 ↗ “ZD6474 (vandetanib)” NCT00098345 ↗ “Vandetanib.” NCT02142036 ↗ |
| Known as | AZD6474 | “A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)” NCT01586624 ↗ |
| Known as | CAPRELSA | “A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects when a Single Oral Dose of Vandetanib 300 mg...” NCT01539655 ↗4“A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination with...” NCT01544140 ↗ “with a Single Dose of Vandetanib (CAPRELSA) 300 mg” NCT01561781 ↗ “Vandetanib (CAPRELSA) 800 mg” NCT01551615 ↗ “Caprelsa (vandetanib)” NCT01601808 ↗ |
| Known as | Caprelsa(R) | “Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors” NCT02015065 ↗ |
| Known as | GNF-PF-2188 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | NSC-744325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | NSC-760766 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | SAR390530 | “Vandetanib (SAR390530)” NCT01876784 ↗ |
| Known as | Vandetanib - Zactima (ZD 6474) | “Vandetanib - Zactima (ZD 6474)” NCT00613223 ↗ |
| Known as | Zactima | “Vandetanib (ZACTIMA; ZD6474; AstraZeneca) is an oral small molecule antineoplastic drug that inhibits vascular endothelial growth factor receptor 2 (VEGFR2), estimated...” NCT02015065 ↗9“A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or...” NCT00923247 ↗ “This study will examine the effectiveness of an investigational drug called ZD6474 (also known as vandetanib or ZACTIMA).” NCT00566995 ↗ “This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474).” NCT00667147 ↗ “ZD6474 (Zactima) 100mg” NCT00496509 ↗ “Zactima (vandetanib)” NCT00498797 ↗ “Zactima (ZD6474)” NCT00496275 ↗ |
| Known as | ZD-64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | ZD6474 | “A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca...” NCT01876784 ↗42“Vandetanib (CAPRELSA; ZD6474) potently inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), and shows additional inhibitory activity at sub-micromolar...” NCT00923247 ↗ “Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian...” NCT00872989 ↗ “This was a parallel group, randomized, double blind, placebo controlled, multicentre study designed to assess whether vandetanib (ZD6474) conferred an improvement in PFS as...” NCT00537095 ↗ “Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas” NCT00734890 ↗ “In vivo experiments have documented the ability of vandetanib (ZD6474) to inhibit tumor growth in various preclinical tumor models.” NCT00995007 ↗ “This study will examine the effectiveness of an investigational drug called ZD6474 (also known as vandetanib or ZACTIMA).” NCT00566995 ↗ “Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors” NCT02015065 ↗ “This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474).” NCT00667147 ↗ “ZD6474 (Vandetanib at the dose of 100 mg)” NCT00752986 ↗ “ZD6474 (vandetanib) 100mg” NCT00506051 ↗ “ZD6474 (Vandetanib)” NCT00807170 ↗ “ZD6474 (vandetanib)” NCT01004419 ↗ “ZD6474 (Vandetanib)” NCT00410761 ↗ “Vandetanib (ZD6474)” NCT00494481 ↗ “ZD6474, Vandetanib” NCT00753675 ↗ “ZD6474, Vandetanib” NCT00753714 ↗ |
| Action | Inhibit | “vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors” PMID 17878480 ↗ Sep 20073“Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL24828 ↗ “Tyrosine-protein kinase SRC inhibitor” CHEMBL24828 ↗ “Tyrosine-protein kinase BRK inhibitor” CHEMBL24828 ↗ |
| Modality | Small molecule | “Vandetanib is a novel oral molecule (anilinoquinazoline)” NCT00687297 ↗ |
| Route | Oral | “300-mg Daily Oral Dose” NCT00034918 ↗ |
| Target | EGFR | “vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling” PMID 25881079 ↗ Mar 2015 |
| Target | PTK6 | “Tyrosine-protein kinase BRK inhibitor” CHEMBL24828 ↗ |
| Target | RET | “vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling” PMID 25881079 ↗ Mar 2015 |
| Target | SRC | “Tyrosine-protein kinase SRC inhibitor” CHEMBL24828 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL24828 ↗ |